Cite
MLA Citation
S. Popat et al.. “3085 Second-line afatinib vs erlotinib in patients with advanced squamous cell carcinoma (SCC) of the lung: patient-reported outcome (PRO) data from the global LUX-Lung 8 (LL8) Phase III trial.” European journal of cancer, vol. 51, n.d., pp. S626–S627. http://access.bl.uk/ark:/81055/vdc_100030628321.0x00004c